Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial

Background: The POTENT trial compared the safety and efficacy of tipranavir/ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each with an optimized background regimen (OBR) in triple-class experienced HIV-1-infected patients with resistance to more than one protease inhibitor (PI). Methodology/Prin...

Descripción completa

Detalles Bibliográficos
Autores principales: Elgadi, Mabrouk M., Piliero, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585832/
https://www.ncbi.nlm.nih.gov/pubmed/22007990
http://dx.doi.org/10.2165/11596340-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585832/
https://www.ncbi.nlm.nih.gov/pubmed/22007990
http://dx.doi.org/10.2165/11596340-000000000-00000

Ejemplares similares